Gene transfer of heme oxygenase-1 and carbon monoxide delivery inhibit chronic rejection

Area of Science:

• Vascular biology
• Transplantation immunology
• Gene therapy

Background:

• Chronic rejection involves intimal hyperplasia, a process driven by leukocyte infiltration and smooth muscle cell proliferation.
• Heme oxygenase-1 (HO-1) is a cytoprotective enzyme that metabolizes heme into beneficial compounds like carbon monoxide (CO).

Purpose of the Study:

• To investigate the therapeutic potential of HO-1 gene transfer and CO delivery in mitigating chronic allogeneic aorta rejection in a rat model.
• To compare the efficacy of adenoviral vector-mediated HO-1 gene transfer (AdHO-1) versus CO administration.

Main Methods:

• Adenoviral vector-mediated HO-1 gene transfer into rat aorta endothelial cells (ECs).
• Carbon monoxide (CO) delivery using methylene chloride (MC) as a CO-releasing agent.
• Assessment of intimal thickness, leukocyte infiltration, adhesion molecules, costimulatory molecules, cytokines, and VSMC accumulation.

Main Results:

• Both AdHO-1 gene transfer and CO treatment significantly reduced intimal thickness and leukocyte infiltration compared to controls.
• AdHO-1 showed a more pronounced reduction in leukocytes and inflammatory markers, while CO was more effective in inhibiting VSMC accumulation.
• Gene transfer demonstrated a more comprehensive effect on reducing inflammatory cell infiltration and expression of associated molecules.

Conclusions:

• HO-1 gene transfer and CO delivery represent promising novel strategies for managing chronic transplant rejection.
• Targeting HO-1 and modulating CO levels offer distinct yet complementary therapeutic benefits in preventing vascular complications of chronic rejection.